Map Pharmaceutical’s Phase III Trial Of Migraine Drug Meets All Primary Endpoints
The trial (Freedom-301), a multi-center, randomized, double-blind, placebo-controlled Phase 3 trial designed to evaluate the safety and efficacy of Levadex as a potential treatment for acute migraine. Primary
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.